Skip to main content
Article thumbnail
Location of Repository

Chronic kidney disease mineral and bone disorder in children

By Katherine Wesseling, Sevcan Bakkaloglu and Isidro Salusky

Abstract

Childhood and adolescence are crucial times for the development of a healthy skeletal and cardiovascular system. Disordered mineral and bone metabolism accompany chronic kidney disease (CKD) and present significant obstacles to optimal bone strength, final adult height, and cardiovascular health. Decreased activity of renal 1 alpha hydroxylase results in decreased intestinal calcium absorption, increased serum parathyroid hormone levels, and high-turnover renal osteodystrophy, with subsequent growth failure. Simultaneously, phosphorus retention exacerbates secondary hyperparathyroidism, and elevated levels contribute to cardiovascular disease. Treatment of hyperphosphatemia and secondary hyperparathyroidism improves growth and high-turnover bone disease. However, target ranges for serum calcium, phosphorus, and parathyroid hormone (PTH) levels vary according to stage of CKD. Since over-treatment may result in adynamic bone disease, growth failure, hypercalcemia, and progression of cardiovascular calcifications, therapy must be carefully adjusted to maintain optimal serum biochemical parameters according to stage of CKD. Newer therapeutic agents, including calcium-free phosphate binding agents and new vitamin D analogues, effectively suppress serum PTH levels while limiting intestinal calcium absorption and may provide future therapeutic alternatives for children with CKD

Topics: Educational Feature
Publisher: Springer-Verlag
OAI identifier: oai:pubmedcentral.nih.gov:2668632
Provided by: PubMed Central

Suggested articles

Citations

  1. (2002). 204 Pediatr Nephrol (2008) 23:195–207Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure.
  2. (1982). 25-hydroxyvitamin D3 (calcifediol) therapy of juvenile renal osteodystrophy: beneficial effect on linear growth velocity.
  3. (1999). A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients.
  4. (1975). A comparison of the effects of the calcitonins, steroid hormones and thyroid hormones on the response of bone to parathyroid hormone in tissue culture.
  5. (1996). A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism.
  6. (2003). A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
  7. (1992). Accelerated growth in short children with chronic renal failure treated with both strict dietary therapy and recombinant growth hormone.
  8. (2002). Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure.
  9. (2006). Akizawa T
  10. (1983). Aluminum is associated with low bone formation in patients receiving chronic parenteral nutrition.
  11. (2004). Arterial calcifications and bone histomorphometry in end-stage renal disease.
  12. (2003). Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study.
  13. (2007). Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients.
  14. (2000). Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.
  15. b (after correction of acidosis, anemia and secondary hyperparathyroidism)
  16. (2008). b (lanthanum carbonate) Pediatr Nephrol
  17. b (nutritional assessment and phosphate restriction)
  18. (1994). Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD.
  19. (1988). Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD.
  20. c (switching to non-calcium phosphate binder)
  21. (2001). Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells.
  22. (1999). Calcium sensing in cultured chondrogenic RCJ3.1C5.18 cells.
  23. (2005). Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: role of calcium-phosphorus metabolism.
  24. (2002). Cardiovascular disease in pediatric chronic dialysis patients.
  25. (2003). Catch-up growth with normal parathyroid hormone levels in chronic renal failure.
  26. (2004). Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
  27. (2005). Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
  28. (2005). Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis.
  29. (2003). Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.
  30. (2002). Cis and trans acting factors in the regulation of parathyroid hormone (PTH) mRNA stability by calcium and phosphate.
  31. (2003). Control of parathyroid cell growth by calcimimetics.
  32. (2004). Coronary artery calcification in patients with CRF not undergoing dialysis.
  33. (2000). Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis.
  34. (2006). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).
  35. (1997). Derangements of the somatotropic hormone axis in chronic renal failure. Kidney Int Suppl 58:S106–S113
  36. (2005). Determinants of peak bone mineral density and bone area in young women.
  37. (2004). Determinants of progressive vascular calcification in haemodialysis patients.
  38. (2006). Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men.
  39. (1998). Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD.
  40. (1990). Disturbance of growth hormone-insulin-like growth factor axis in uraemia. Implications for recombinant human growth hormone treatment.
  41. (2004). Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.
  42. (1995). Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure.
  43. (1988). Effect of calcium depletion on the rat parathyroids.
  44. (1984). Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.
  45. (2006). Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin D in chronic kidney disease. Nephrology
  46. (2005). Effect of pravastatin in people with diabetes and chronic kidney disease.
  47. (1986). Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis.
  48. (2005). Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.
  49. (2004). Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.
  50. (2004). Emans SJ
  51. (2006). European Pediatric Dialysis Working Group (EPDWG)
  52. (1971). Evidence for a new kidney-produced hormone, 1,25-dihydroxycholecalciferol, the proposed biologically active form of vitamin D.
  53. (2006). Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up.
  54. (2001). FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate.
  55. (2005). Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.
  56. (2005). First- and secondgeneration immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl.
  57. (2004). Fosrenol (lanthanum carbonate). Product package insert
  58. (2005). German Diabetes and Dialysis Study Investigators
  59. (1994). Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized doubleblind placebo-controlled study.
  60. (2003). Growth in children with chronic renal failure on intermittent versus daily calcitriol.
  61. (1998). Growth of long bones in renal failure: roles of hyperparathyroidism, growth hormone and calcitriol.
  62. (1988). Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure.
  63. (1986). Iliac crest bone biopsy for diagnosis of aluminum toxicity and a guide to the use of deferoxamine.
  64. (2007). Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
  65. (2001). Improved assessment of bone turnover by the PTH-(1–84)/large C-PTH fragments ratio in ESRD patients.
  66. (1993). In situ localization of PTH/PTHrP receptor mRNA in the bone of fetal and young rats.
  67. (2002). Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.
  68. (2002). Increased levels of osteoprotegerin in hemodialysis patients.
  69. (2001). Insights into the mechanism of vascular calcification.
  70. (2006). Intensified and daily hemodialysis in children might improve statural growth.
  71. (1998). Intermittent calcitriol therapy and growth in children with chronic renal failure.
  72. (2005). Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 101:c94–c99
  73. (2005). K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease.
  74. (2005). Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study.
  75. (2003). Matrix Gla protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats.
  76. (2002). Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins.
  77. (2007). Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients.
  78. (2002). noninvasive diagnosis of renal bone disease.
  79. (1986). Oral calcium carbonate as phosphate-binder in infants and children with chronic renal failure. Miner Electrolyte Metab 12:320–325 Pediatr Nephrol
  80. (1997). Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation.
  81. (1991). Parathyroid cell number and size in hypocalcemic young rats.
  82. (1995). Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D.
  83. (2005). Parathyroid hormone and growth in children with chronic renal failure.
  84. (2006). Pediatric Renal Transplant Cooperative (2006) North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)
  85. (2000). Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87:E10–E17
  86. (2002). Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells.
  87. (2005). Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients.
  88. (2007). Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.
  89. (2005). Progressive accumulation of lanthanum in the liver of normal and uremic rats.
  90. (2004). Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate.
  91. (2002). Regulation of arachidonic acid production by intracellular calcium in parathyroid cells: effect of extracellular phosphate.
  92. (2006). Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women.
  93. (1999). RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
  94. (1990). Renal bone disease 1990: an unmet challenge for the nephrologist.
  95. (1986). Renal osteodystrophy.
  96. (2006). Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients.
  97. (1986). Serum bone Gla-protein in renal osteodystrophy: comparison with bone histomorphometry.
  98. (2005). Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.
  99. (2002). Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.
  100. (2005). Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
  101. (2003). Sevelamer hydrochloride: an effective phosphate binder in dialyzed children.
  102. (2003). Severe bone disease and low bone mineral density after juvenile renal failure.
  103. (1999). Sharma A
  104. (2003). Similar predictive value of bone turnover using first- and secondgeneration immunometric PTH assays in pediatric patients treated with peritoneal dialysis.
  105. (1973). Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects.
  106. (1975). Slipped epiphyses in renal osteodystrophy.
  107. (1990). Soft tissue calcification in pediatric patients with end-stage renal disease.
  108. (1994). Stimulation of growth by recombinant human growth hormone in children undergoing peritoneal or hemodialysis treatment. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. Adv Perit Dial 10:321–326
  109. (2005). Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism.
  110. (2002). The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.
  111. (1997). The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure.
  112. (1998). The insulin-like growth factor axis and growth in children with chronic renal failure: a report of the Southwest Pediatric Nephrology Study Group.
  113. (1989). The parathyroid glands in chronic renal failure: a study of their growth and other properties made on the basis of findings in patients with hypercalcemia.
  114. (2003). The serum protein alpha 2-Heremans-Schmid glycoprotein/ fetuin-A is a systemically acting inhibitor of ectopic calcification.
  115. (1996). The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis.
  116. (1993). The spectrum of bone disease in end-stage renal failure-an evolving disorder.
  117. (2002). Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism.
  118. (1970). Unique biosynthesis by kidney of a biological active vitamin D metabolite.
  119. (2003). Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels.
  120. (1997). Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis.
  121. (1971). Vitamin D metabolism: the role of kidney tissue.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.